| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 47.850 | 24.033 | 26.451 | 11.842 | 15.935 | 14.364 | 23.972 | 17.557 | 6.941 | 8.825 |
| Total Income - EUR | 47.850 | 24.034 | 26.451 | 11.842 | 15.935 | 14.366 | 23.973 | 17.559 | 6.942 | 8.825 |
| Total Expenses - EUR | 6.984 | 8.578 | 7.790 | 5.966 | 5.842 | 5.488 | 9.989 | 13.228 | 7.950 | 8.318 |
| Gross Profit/Loss - EUR | 40.866 | 15.456 | 18.661 | 5.876 | 10.093 | 8.878 | 13.985 | 4.331 | -1.009 | 507 |
| Net Profit/Loss - EUR | 39.431 | 14.735 | 17.867 | 5.521 | 9.615 | 8.443 | 13.265 | 3.815 | -1.009 | 341 |
| Employees | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Nipamed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 898 | 3.474 | 2.334 | 1.269 | 241 | 12.646 | 9.355 | 5.753 | 2.116 | 850 |
| Current Assets | 49.055 | 12.504 | 16.465 | 5.462 | 10.082 | 3.388 | 5.504 | 7.297 | 2.386 | 1.041 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 419 | 0 | 6.053 | 2.864 | 150 | 3.024 | 3.463 | 4.946 | 0 | 83 |
| Cash | 48.636 | 12.504 | 10.412 | 2.598 | 9.931 | 364 | 2.041 | 2.351 | 2.386 | 958 |
| Shareholders Funds | 39.476 | 14.780 | 17.912 | 5.564 | 9.657 | 8.484 | 13.306 | 3.855 | 736 | 1.074 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 10.477 | 1.198 | 887 | 1.167 | 665 | 7.550 | 1.553 | 9.195 | 3.766 | 817 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3313 - 3313" | |||||||||
| CAEN Financial Year |
3319
|
|||||||||
Comments - Nipamed S.r.l.